Get direct access to interviews with experts, as well as the latest data and clinical news updates, straight from the conference floor in Los Angeles.
February 13th 2025
A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden
March 1, 2025
Register Now!
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
Study Identifies Key Inflammatory Markers in Pediatric MOGAD, Suggesting New Therapeutic Targets
February 13th 2025A recent study reported significantly elevated cerebrospinal fluid inflammatory markers in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease during acute phases.
FDA Grants Fast Track Designation to Promising Multiple System Atrophy Agent Amlenetug
Amlenetug, a human monoclonal antibody that recognizes and binds to all major forms of extracellular α-synuclein, is currently being assessed in a large-scale phase 3 trial to determine its therapeutic potential as a treatment for MSA.
Breaking Down ISC 2025: Key Takeaways From Experts in Stroke Neurology
Stroke neurologists Lauren Sansing, MD, MS, FAHA, FANA, and Bijoy Menon, MD, MSc, FRCPC, provided a post-conference perspective on the emerging data and research presented at the 2025 International Stroke Conference.
Dubai Study Highlights Disease Characteristics and Treatment Outcomes in NMOSD and MOGAD
February 12th 2025A 5-year retrospective analysis offered insights into disease characteristics, treatment responses, and clinical outcomes of neuromyelitis optica spectrum disorder as well as myelin oligodendrocyte glycoprotein antibody-associated disease.
NeuroVoices: Véronique Miron, PhD, on Exciting Developments and Expectations for ACTRIMS 2025
The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave an overview for the upcoming ACTRIMS Forum, highlighting key sessions, themes, and advances in the multiple sclerosis field.
Case Report Reveals Promising Efficacy of Ofatumumab as Long-Term Treatment in Relapsing CIDP
February 11th 2025In a recent case report, a 46-year-old man living with chronic inflammatory demyelinating polyneuropathy experienced multiple relapses despite various conventional treatments; however, found promise in ofatumumab, an approved drug for multiple sclerosis.
FDA Accepts NDA Application for Troriluzole as Potential First Treatment for Spinocerebellar Ataxia
Troriluzole, a new chemical entity and third-generation novel prodrug that modulates glutamate, would become the first approved agent for SCA, pending the FDA’s clearance.
Low-Dose Interleukin-2 Reduces Proinflammatory Biomarkers in Phase 2 Study of Alzheimer Disease
Monthly cycles of low-dose IL-2, or COYA 301, resulted in statistically significant decreases in proinflammatory biomarkers and increases in anti-inflammatory cytokine IL-4 vs placebo.